Targeting Galectin 3 illuminates its contributions to the pathology of uterine serous carcinoma

Yusuke Matoba,Dominique T. Zarrella,Venkatesh Pooladanda,Maryam Azimi Mohammadabadi,Eugene Kim,Shaan Kumar,Mengyao Xu,Xingping Qin,Lauren J Ray,Kyle M. Devins,Raj Kumar,Artem Kononenko,Eric Eisenhauer,Irva E. Veillard,Wataru Yamagami,Sarah J. Hill,Kristopher A. Sarosiek,Oladapo O. Yeku,David R. Spriggs,Bo R. Rueda
DOI: https://doi.org/10.1038/s41416-024-02621-x
IF: 9.075
2024-03-05
British Journal of Cancer
Abstract:Uterine serous cancer (USC) comprises around 10% of all uterine cancers. However, USC accounts for approximately 40% of uterine cancer deaths, which is attributed to tumor aggressiveness and limited effective treatment. Galectin 3 (Gal3) has been implicated in promoting aggressive features in some malignancies. However, Gal3's role in promoting USC pathology is lacking.
oncology
What problem does this paper attempt to address?